As part of a program of postmarketing surveillance, the use of jlumazenil was monitored prospectively in a New Zealand public hospital for a period of twelve months. A questionnaire on usage, efficacy and side-effects was completed by clinicians for 118 patients receiving the drug. Our conclusions are these: 1. Flumazenil was used most frequently after anaesthesia and in the initial management of intentional drug overdose. 2. In two-thirds of cases, jlumazenil was used to antagonise benzodiazepines in the presence of non-benzodiazepine drugs and its efficacy was primarily determined by the presence of these latter drugs. 3. The complications of jlumazenil are mild although important complications may arise from interaction with other drugs and unmasking of conditions such as postoperative pain. 4. Resedation was common (24%), although rarely a problem unless large doses of benzodiazepine agonist had been administered or if other hypnosedatives were given subsequently.
METHOD
Over a twelve-month period, each ampoule of flumazenil dispensed by the hospital pharmacy was accompanied by a two-page questionnaire for completion by the physician giving the medication. This document comprised a series of specific questions seeking 1. patient demographic data; 2. the reason for flumazenil administration; 3. the name, time and doses of all drugs received by the patient prior to flumazenil administration; 4. the dose and method of administration of flumazenil; 5. whether additional doses were needed; 6. the degree of sedation on a five-point scale (Table 1) prior to and following administration; 7. the presence of specifically listed side-effects (Table 4) ; 8 . the values of any physiological recordings taken and 9. whether the clinician thought that 'the administration of flumazenil had reduced the need for patient supervision' or had 'increased the degree of patient safety'.
During the study, flumazenil was freely available within the operating theatres, recovery area, intensive care units and the accident and emergency department, with smaller stocks available to medical and surgical wards and outpatient clinics. The data presented here includes only those cases where the drug was used clinically and not for research. In order to ensure the highest return rate for questionnaires, it was arranged that restocking of ward flumazenil supplies was made upon return of the completed questionnaires to the hospital pharmacy.
While it was probable that some patients received flumazenil without a questionnaire being completed, comparison of known ampoule usage against questionnaire returns indicated a return rate in excess of 80%.
Statistical analysis of parametric, betweengroup comparisons was by ANOV A and analysis of sedation scores used the Kruskal-Wallis ANOVA.
RESULTS
Over the twelve-month study period, completed forms were returned for 118 patients, mean age 51.3 yr (SD 23), weight 67.8 kg (SO 17.5) and 56% male. Two-thirds received flumazenil for elective reversal ofBZ agonist sedation or hypnosis and one-third for therapeutic or diagnostic reasons. Areas of most frequent use were operating theatres and recovery (52%), accident and emergency department (23%) and intensive care (11 %).
In Table 2 the dose and response to flumazenil are given according to reasons for usage. Significant differences were seen in flumazenil dose (P < 0.02), and in sedation scores before (P < 0.01) and after flumazenil (P<O.Ol) with largest doses given to those where the reversal effect was least, for the diagnosis of coma and intentional drug overdose. Smallest doses and most effective reversal were seen after BZ sedation for minor procedures. Table 3 shows the response to flumazenil according to the drug combination ingested (non-BZ hypnosedatives included alcohol, Acupan, [nefopam hydrochloride], Sinequan, [doxepin hydrochloride], chloral hydrate, hashish, barbiturate, and dextropropoxyphene). Significant differences were found in flumazenil dose (P < 0.0001) and postflumazenil sedation score (P = 0.0003) but not pre-injection sedation score. Greatest arousal was observed in the group ingesting only a BZ agonist and no response seen in those who had only ingested non-BZ hypnosedatives. Where the class of drug was not known, four of five patients showed signs of lightening although in only two was it considered to be of clinical value.
In 68% of cases clinicians felt flumazenil had increased patient safety and in 42% had reduced the requirement for patient supervision. In three cases, flumazenil was noted to have been an aid in the diagnosis of coma or slow postoperative recovery. Anaesthetists also commented that following anaesthesia flumazenil was of benefit to patients with ventilatory disease and, where respiratory depression was due to a combination of opioid and BZ agonist, reversal of the BZ component improved ventilation without the need to antagonise the opioid. In six cases the flumazenil was administered because of respiratory depression either due to a BZ alone (4), BZ plus anaesthetics (1) or BZ plus non-BZ hypnosedative (1). The ventilatory response was noted to be excellent in three of the BZ alone group and satisfactory in the others. Resedation was recorded in 24%, one-third of these resedating to a sedation score equal to that prior to the flumazenil injection. One postoperative patient re sedated to a deeper level of sedation although this was considered to be due to the combined effects of residual anaesthesia and the effects of postoperative opioid analgesia, administered after flumazeniL Serious resedation occurred in only one case, given flumazenil after total intravenous anaesthesia using midazolam (total 120 mg) and alfentaniL In all cases the onset of resedation was observed to have occurred within the first hour. Additional flumazenil was given, ten or more minutes after the first dose, to seventeen cases, of which nine doses were for the treatment of resedation. Mean time to the second dose in resedating patients was 39.7 (range 7-120) minutes.
Side-effects were infrequent, generally mild and occurred only in those patients showing signs of arousal, indicating the absence of nonspecific effects (Table 4 ). It was difficult, however, to separate those side-effects directly due to flumazenil from the unmasked effect of other agents or conditions.
Overall, 33% of patients were noted to have had significant pre-existing respiratory disease, 37% cardiovascular disease, 10% were thought to be alcoholic, one patient was an epileptic and 12% were taking chronic BZ medication. No relationship was found between these conditions and side-effects.
Overall, clinicians classified the response to flumazenil as 'excellent' in 22%, 'good' in 38%, 'satisfactory' in 22% and 'poor' in 19%. DISCUSSION Although many studies have demonstrated the efficacy of flumazenil in reversing the sedative effects of BZ agonists,I-3 most have been under the controlled conditions of clinical research. In this study we sought to examine routine clinical usage of the drug. Each of the main indications for flumazenil described by Geller 4 is represented in the survey; reversal of BZ sedation, postoperatively, as a diagnostic tool in coma, and for intentional drug overdose.
Although many non-BZ hypnosedatives (e.g. alcohol, barbiturates), act at the GABA A receptor, flumazenil was uniformly ineffective where sedation was not induced, in part, by a BZ agonist. 5, 6 However, the presence (in 68% of patients) of non-BZ sedatives in addition to the BZ agonist was a major factor in determining the efficacy of the antagonist.
Resedation was common and a predictable result considering the disparate pharmacokinetic profiles of the short-acting flumazenil, compared with the available BZ agonists, and the high affinity of flumazenil for the BZ receptor, allowing small doses to be used with good initial effect. 7 Resedation was seen especially where either the dose of flumazenil was small in relation to the agonist or where other non-BZ hypnosedatives had been ingested or given soon after reversal. One-third of resedating patients returned to similar or deeper levels of sedation to that present before the flumazenil. However, each of these cases had, in addition to a BZ agonist, ingested other non-BZ hypnosedatives or had other reasons for impaired consciousness or had received high doses of BZ agonist. Only one serious case of resedation was observed, after reversal of high dose midazolaml alfentanil anaesthesia.
Prior to this survey we described a major complication offlumazenil 8 in which a patient developed cardiac irritability when a bolus of flumazenil was used after an intentional overdose ofBZ agonist combined with chloral hydrate. It was presumed that the arrhythmia arose due to a combination of agitation and sympathoadrenal actIVIty produced by reversal of sedation and the direct arrhythmogenic effect of chloral hydrate. In the present series, one case of intentional overdose was given flumazenil where, unknown to the clinician, chloral hydrate was the sole agent ingested. No arrhythmia and no lightening were observed, suggesting no direct interaction between the two drugs in the absence of BZ agonist reversal. The case suggested, however, that when the nature of drug-induced coma is not known, flumazenil should be given slowly, under strict supervision and under electrocardiographic monitoring.
Flumazenil was most frequently used for the postoperative antagonism of BZ balanced anaesthesia and a specific advantage was felt to be that it allowed rapid postoperative recovery in patients with impaired ventilatory function. The literature on this subject is unclear, however. Several papers have indicated that flumazenil may not completely antagonise BZ-induced ventilatory depression,9,lo while others have shown it to antagonise midazolam apnoea in volunteers, 11 after midazolam/alfentanil anaesthesia to improve FEV and VC 12 and, after fl uni trazepam/fentanyllni trous oxide anaesthesia to significantly improve arterial blood gas values.13 There is therefore a need for clarification of this issue before antagonised benzodiazepine anaesthesia can be recommended for patients with ventilatory disease. Three patients suffered severe, unmasked postoperative pain after antagonism of the benzodiazepine component, a complication thought to be due to inadequate analgesia and the too rapid, bolus administration of 0.5 mg of the antagonist.
In summary, during twelve months of clinical use, flumazenil was observed to be a safe and effective antagonist of benzodiazepine agonist action. Reported sideeffects were mild and for the majority of cases, the drug was felt to have enhanced patient safety. An important determinant of flumazenil action was the presence of other background conditions or centrally acting drugs. 
